Following the release of Quidel’s Q2 2020 results;
Dara Lo, Medical Device Analyst at GlobalData, a leading data and analytics company, offers her view:
“Quidel has risen dramatically this year due to its flexible, diverse and speedy COVID-19 offerings. With the pandemic still present, especially in the US and South America, and the threat of a second wave hanging over, GlobalData predicts that Quidel’s revenues will continue to climb.
“Quidel’s COVID-19 testing was one of the first to receive Food and Drug Administration (FDA) emergency use authorization, giving the company a significant advantage over its competitors. Not only has Quidel produced several COVID-19 tests since, but the company has also positioned its tests to be truly flexible in terms of the PCR machine needed to run the test, as well as the type of patient sample collected.
“In May, Quidel launched what is still the first and only protein-based antigen COVID-19 test on the market. This technology allows for the rapid detection of a COVID-19 infection in 15 minutes with an easy-to-use automated system. With 43,000 of the instruments required to run the COVID-19 antigen test already installed worldwide, Quidel was able to provide rapid COVID-19 testing for essential workers such as first responders and healthcare workers. Although many companies have felt the hit of COVID-19 on sales, Quidel has been able to rapidly adapt and respond to the pandemic.”